92 related articles for article (PubMed ID: 25683324)
1. Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans.
Becker A; von Richter O; Kovar A; Scheible H; van Lier JJ; Johne A
J Clin Pharmacol; 2015 Jul; 55(7):815-24. PubMed ID: 25683324
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.
Eskens FA; Dumez H; Hoekstra R; Perschl A; Brindley C; Böttcher S; Wynendaele W; Drevs J; Verweij J; van Oosterom AT
Eur J Cancer; 2003 May; 39(7):917-26. PubMed ID: 12706360
[TBL] [Abstract][Full Text] [Related]
3. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.
Mikkelsen T; Brodie C; Finniss S; Berens ME; Rennert JL; Nelson K; Lemke N; Brown SL; Hahn D; Neuteboom B; Goodman SL
Int J Cancer; 2009 Jun; 124(11):2719-27. PubMed ID: 19199360
[TBL] [Abstract][Full Text] [Related]
4. [The inhibitor of integrins Cilengitide: a new active drug in neuro-oncology].
Leblond P; Meignan S; Le Tinier F; Bethe U; Lansiaux A
Bull Cancer; 2011 Oct; 98(9):1083-90. PubMed ID: 21914576
[TBL] [Abstract][Full Text] [Related]
5. Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction.
Leblond P; Dewitte A; Le Tinier F; Bal-Mahieu C; Baroncini M; Sarrazin T; Lartigau E; Lansiaux A; Meignan S
Anticancer Drugs; 2013 Sep; 24(8):818-25. PubMed ID: 23728220
[TBL] [Abstract][Full Text] [Related]
6. Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.
Cheng NC; van Zandwijk N; Reid G
PLoS One; 2014; 9(3):e90374. PubMed ID: 24595274
[TBL] [Abstract][Full Text] [Related]
7. Targeting αvβ3 and αvβ5 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model.
Gvozdenovic A; Boro A; Meier D; Bode-Lesniewska B; Born W; Muff R; Fuchs B
Oncotarget; 2016 Aug; 7(34):55141-55154. PubMed ID: 27409827
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.
MacDonald TJ; Stewart CF; Kocak M; Goldman S; Ellenbogen RG; Phillips P; Lafond D; Poussaint TY; Kieran MW; Boyett JM; Kun LE
J Clin Oncol; 2008 Feb; 26(6):919-24. PubMed ID: 18281665
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of continuous infusion cilengitide in patients with solid tumors.
O'Donnell PH; Undevia SD; Stadler WM; Karrison TM; Nicholas MK; Janisch L; Ratain MJ
Invest New Drugs; 2012 Apr; 30(2):604-10. PubMed ID: 20839028
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.
Hariharan S; Gustafson D; Holden S; McConkey D; Davis D; Morrow M; Basche M; Gore L; Zang C; O'Bryant CL; Baron A; Gallemann D; Colevas D; Eckhardt SG
Ann Oncol; 2007 Aug; 18(8):1400-7. PubMed ID: 17693653
[TBL] [Abstract][Full Text] [Related]
11. The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model.
Ten Hagen TL; Seynhaeve AL; de Wiel-Ambagtsheer Ga; de Bruijn EA; van Tiel ST; Ruegg C; Meyring M; Grell M; Goodman SL; Eggermont AM
Int J Cancer; 2013 Jun; 132(11):2694-704. PubMed ID: 23152080
[TBL] [Abstract][Full Text] [Related]
12. Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models.
Albert JM; Cao C; Geng L; Leavitt L; Hallahan DE; Lu B
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1536-43. PubMed ID: 16863930
[TBL] [Abstract][Full Text] [Related]
13. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
[TBL] [Abstract][Full Text] [Related]
14. Disposition and metabolism of [¹⁴C]PTZ601 in healthy volunteers.
Flarakos J; Ting LS; Du Y; Stein DS; Reynolds CV; Patel M; Roy S; Mangold JB
Xenobiotica; 2013 Mar; 43(3):283-92. PubMed ID: 22931187
[TBL] [Abstract][Full Text] [Related]
15. Disposition and metabolism of radiolabeled casopitant in humans.
Pellegatti M; Bordini E; Fizzotti P; Roberts A; Johnson BM
Drug Metab Dispos; 2009 Aug; 37(8):1635-45. PubMed ID: 19420128
[TBL] [Abstract][Full Text] [Related]
16. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
Burke PA; DeNardo SJ; Miers LA; Lamborn KR; Matzku S; DeNardo GL
Cancer Res; 2002 Aug; 62(15):4263-72. PubMed ID: 12154028
[TBL] [Abstract][Full Text] [Related]
17. Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of αvβ5 integrin.
Ruffini F; Graziani G; Levati L; Tentori L; D'Atri S; Lacal PM
Int J Cancer; 2015 Mar; 136(6):E545-58. PubMed ID: 25284767
[TBL] [Abstract][Full Text] [Related]
18. The integrin inhibitor cilengitide affects meningioma cell motility and invasion.
Wilisch-Neumann A; Kliese N; Pachow D; Schneider T; Warnke JP; Braunsdorf WE; Böhmer FD; Hass P; Pasemann D; Helbing C; Kirches E; Mawrin C
Clin Cancer Res; 2013 Oct; 19(19):5402-12. PubMed ID: 23948974
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo drug disposition of cilengitide in animals and human.
Dolgos H; Freisleben A; Wimmer E; Scheible H; Krätzer F; Yamagata T; Gallemann D; Fluck M
Pharmacol Res Perspect; 2016 Apr; 4(2):e00217. PubMed ID: 27069630
[TBL] [Abstract][Full Text] [Related]
20. Effects of cilengitide in osteoclast maturation and behavior.
Chillà A; Bianconi D; Geetha N; Dorda A; Poettler M; Unseld M; Sykoutri D; Redlich K; Zielinski CC; Prager GW
Exp Cell Res; 2015 Sep; 337(1):68-75. PubMed ID: 26209605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
